Author Interview: Professor Martin Bergman, 2023

Professor Peter Nash from the Griffith University in Brisbane, is joined by Professor Martin Bergman, a Clinical Associate Professor of Medicine at the Drexel University College of Medicine in Philadelphia, to discuss his recent paper ‘One-Year Medication Adherence and Persistence in Rheumatoid Arthritis in Clinical Practice: A Retrospective Analysis of Upadacitinib, Adalimumab, Baricitinib, and Tofacitinib.’

Detailed summary slides of this paper and many more publications, are free to view and download in the publications section at imidforum.com.

Upadacitinib treating bDMARD-IR PsA & Post-marketing surveillance of tofacitinib treating PsA & RA

Peter Nash, Professor at the School of Medicine, Griffith University, and Director of the Rheumatology Research Unit on the Sunshine Coast, Australia, is joined by Laura Coates, an Associate Professor, NIHR clinician scientist and senior clinical research fellow at the Oxford Psoriatic Arthritis Centre as well as Doctor Frank Behrens, Medical director at Goethe-University.

The papers covered in this topical discussion highlight two interesting areas of the modern PsA therapeutic landscape. The first of the publications discusses the safety and efficacy of upadacitinib in the treatment of patients with PsA and an inadequate response to bDMARDs through a three-year study. The second, explores an analysis of the real-world safety profile of tofacitinib in the treatment of patients with PsA.

If you would like to read more about the topics discussed, head over to cytokinesignalling.com, where you’ll find detailed summary slides of each of the papers.

AxSpA Podcast: The Efficacy and Safety of Ixekizumab & Tildrakizumab

Dr Sofia Ramiro, consultant rheumatologist and senior researcher at Zuyderland Medical Centre and Leiden University Medical Centre in the Netherlands, is joined by Professor Hideto Kameda, Professor of Internal Medicine at Toho University and Atul Deodhar, Professor of Medicine and Medical Director of Rheumatology Clinics in the Division of Arthritis & Rheumatic Diseases at Oregon Health & Science University in Portland, USA to discuss the Efficacy and Safety of Ixekizumab & Tildrakizumab.

In the first paper discussed, it describes the safety and efficacy of ixekizumab treatment in patients with r-axSpA and nr-axSpA for up to 156 weeks. The second study discussed goes on to assess the safety and efficacy of tildrakizumab in patients with active AS.

Discussing Rheumatology: September 2023

Join Prof Iain McInnes as he reviews two interesting papers , that retrospectively investigate the properties of JAK inhibitors.

In our first paper, Peter Taylor and his colleagues review the pharmacological differences between JAK inhibitors, and how these may affect safety and efficacy. In the second, Qige Wei and colleagues carried out a network meta-analysis of 14 RCTS to identify any associations between RA therapies and MACE or all-cause mortality.

To access detailed summary slides of the papers discussed, visit imidforum.com.

Author Interview: Sofia Ramiro

Professor Peter Nash from the Griffith University in Brisbane, is joined by Doctor Sofia Ramiro, a Consultant Rheumatologist and Senior Researcher at Leiden University Medical Centre to discuss her recent paper 'Do Fatty Lesions Explain the Effect of Inflammation on New Syndesmophytes in Patients with Radiographic Axial Spondyloarthritis? Results From the SIAS Cohort and ASSERT Trial'

Discussing Rheumatology: August 2023

Join Prof Iain McInnes as he reviews two interesting papers.

Our first paper today by Charles-Schoeman and colleagues compared paraoxonase activity in RA patients treated with tofacitinib, with a focus of PON1 genotypes. Furthermore, the relationship between PON1 genotypes and the risk of MACE and malignancy were also investigated.

In our second paper, Peter Taylor and colleagues evaluated the results of several baricitinib RCTs and real-world evidence studies.